explore -WSS

explore

author：Wikipedia 2025-10-02 21:07:36 - browse：7349

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Illinois Supreme Court finds assault weapons ban constitutional

WSS

Maui wildfire now ranks as the fifth

YouTube cracks down on misinformation on cancer treatment

Biden administration begins canceling student loan debt for 804,000 borrowers

A protest over insulin prices is seen as a fight for life

Mark Cuban is blaming the wrong people for high drug costs

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

entertainment

explore

explore

How to save PrEP access — and even expand it

Padmanee Sharma of MD Anderson at center of lawsuit over credit

As demand for Covid shots wanes, Moderna seeks its next success

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Novavax promises a turnaround & Lilly roils the obesity market

The Biogen Aduhelm mess could happen again

Apple is now the first public company to be valued at $3 trillion

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Bright Health sells Medicare Advantage business to Molina

Readout LOUD: Venture capital, Gilead, and more M&A

entertainment

Gene therapy for Afghan refugees’ infant will be fully covered

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

The Biogen Aduhelm mess could happen again

The Biogen Aduhelm mess could happen again

Senators push IRS to launch nonprofit hospital probe

Unique patient identifier: Experts argue the benefits, pitfalls

focus

knowledge

Wikipedia

hotspot